Research programme: anti-complement monoclonal antibodies - Alexion

Drug Profile

Research programme: anti-complement monoclonal antibodies - Alexion

Alternative Names: 133.3 - Alexion; Anti C5 monoclonal antibody BB5-1 - Alexion; Anti-C8-monoclonal-antibody - Alexion; Monoclonal antibody N19/8 - Alexion; N19/8 - Alexion

Latest Information Update: 28 Feb 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alexion Pharmaceuticals
  • Class Monoclonal antibodies
  • Mechanism of Action Complement C5 inhibitors; Complement C8 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Idiopathic thrombocytopenic purpura; Xenotransplant rejection

Most Recent Events

  • 15 Dec 2000 Preclinical development for Idiopathic thrombocytopenic purpura in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top